Compare Neurocrine Biosciences Inc (NBIX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Exxon Mobil Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Exxon Mobil Corporation trades at $151.77 (market cap $614.94B). The key difference: Exxon Mobil Corporation is far larger — about 35.3× Neurocrine Biosciences Inc's market cap, and Exxon Mobil Corporation pays a 2.78% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | XOM | |
|---|---|---|
Market Cap | $17.40B | $614.94B |
Sector | Health | Energy |
52-Week High | $180.55 | $171.52 |
52-Week Low | $123.10 | $105.83 |
Enterprise Value | $16.49B | $654.17B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
ExxonMobil (XOM) trades at $147.39, up 0.99% today, with a bullish technical signal from moving averages and oscillators. The stock has beaten earnings estimates for the last three quarters, though revenue and net income have trended lower since 2022. Analyst consensus is a buy with a $169.78 price target, and recent news highlights the company's Permian Basin advantage and potential oil price spikes.
XOM offers value through strong cash flow and a robust balance sheet, but faces headwinds from declining profitability and net cash outflows. Investment appeal hinges on oil price stability and execution in key growth areas, while risks include volatile energy markets and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
